Research Study Comparing a New Medicine Fast-acting Insulin Aspart to Another Already Available Medicine NovoRapid/NovoLog in People With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1264 participants.

Also called NCT03268005

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,264 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03268005
  • EudraCT 2016-000878-38
Other papers using this trial's data
  • A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9) Diabetes care, 2020-08 DOI, PubMed 32209647, PMC7372057 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Bulgaria, Canada, Croatia, Czechia, Germany, Greece, Italy, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03268005. Randomized; quadruple masking; primary purpose treatment. Start 2017-09-19 (actual); primary completion 2019-01-07 (actual). Results posted on 2020-03-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
Acronym
onset 9
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Faster-acting insulin aspart
Intervention (Drug)
Insulin aspart
Intervention (Drug)
Insulin degludec
Intervention (Drug)
Metformin
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03268005
Content hash
151a0b04e1994f263d3604e06b9670c117cb40034bd64d72b62500c341a7cd93